X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
This DMT study, which is the largest to date, is expected to accelerate the clinical development path of CYB004, Cybin’s proprietary deuterated DMT molecule for the potential treatment of anxiety disorders, by approximately nine months.
Lead Product(s): Deuterated Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: CYB004
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cybin
Deal Size: $1.1 million Upfront Cash: Undisclosed
Deal Type: Acquisition July 11, 2022
Details:
Pending the close of the Acquisition, the CYB004-E study is expected to yield essential safety and dosing optimization data and will replace Cybin’s planned pilot study for CYB004 that was expected to commence in the third quarter of 2022.
Lead Product(s): Deuterated Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: CYB004
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cybin
Deal Size: $1.2 million Upfront Cash: Undisclosed
Deal Type: Acquisition June 07, 2022
Details:
Formulation and stability testing of DMT drug product by CHDR's partner pharmacy has commenced in accordance with projected start date of EBRX-101(N, N-dimethyltryptamine), a study that will evaluate controlled intravenous infusion of population of healthy smokers.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Psychiatry/Psychology Product Name: EBRX-101
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Laboratorium Ofichem B.V
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
